Alterity Therapeutics (NASDAQ:ATHE) announced that a study recently published in the journal Neurotherapeutics demonstrated that its lead clinical asset, ATH434, was neuroprotective…
The COVID-19 pandemic emerged in 2019 in China and spread to the rest of the globe in early 2020.
Since then, the virus has caused more than 6.8 million deaths.
CureVac N.V. (NASDAQ:CVAC) announced extended preliminary data from ongoing Phase 1 programs in COVID-19 and seasonal flu conducted in collaboration with GSK…
The designation is based on topline data from the ConquerRSV Phase 3 efficacy trial, which demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease.The designation is based on topline data from the ConquerRSV Phase 3 efficacy trial, which demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease.
Chronic wounds are a persistent and pricey problem for patients and health care systems around the world.
Defined as “wounds that fail to proceed through the normal phases of wound healing in an orderly and timely manner,” chronic wounds range from severe burns to bedsores to diabetic ulcers.